Get the Stockscreener App
0.3923
8.77%
-0.0377
After Hours:
.41
0.0177
+4.51%
Werewolf Therapeutics Inc stock is traded at $0.3923, with a volume of 578.91K.
It is down -8.77% in the last 24 hours and down -41.42% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.43
Open:
$0.454
24h Volume:
578.91K
Relative Volume:
1.31
Market Cap:
$19.06M
Revenue:
$1.14M
Net Income/Loss:
$-60.82M
P/E Ratio:
-0.2941
EPS:
-1.3338
Net Cash Flow:
$-60.29M
1W Performance:
-12.82%
1M Performance:
-41.42%
6M Performance:
-58.78%
1Y Performance:
-68.11%
1-Day Range:
$0.3869
$0.454
1-Week Range:
$0.3869
$0.4953
52-Week Range:
$0.3869
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.3923 | 20.90M | 1.14M | -60.82M | -60.29M | -1.3338 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock - Investing.com
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock By Investing.com - Investing.com Australia
Werewolf Therapeutics (NASDAQ: HOWL) director-affiliated funds sell 139,803 shares - Stock Titan
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update - Bez Kabli
Werewolf Therapeutics Inc. Q1 2026 Earnings: Narrower Loss Surprises as Pipeline Progress ContinuesCEO Earnings Statement - The Legal Advocate
What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL) - Kavout
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares By Investing.com - Investing.com India
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares - Investing.com
Director-linked funds trim Werewolf (NASDAQ: HOWL) stake via 141K-share sale - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
MPM-linked funds tied to Werewolf (NASDAQ: HOWL) sell 191,762 shares under plan - Stock Titan
HOWL Q1 2026 Earnings: EPS Beats Estimates as Biotech Continues Pipeline ProgressBook Value Growth - The Legal Advocate
HOWL Q1 2026 Earnings: Narrowed Loss Exceeds Estimates, Stock RisesProfit Announcement - Newser
Werewolf Therapeutics (HOWL) Stages a Modest Rebound: Can the $0.44 Level Hold?Impulse Wave - The Legal Advocate
Werewolf Therapeutics (HOWL) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational Discipline - The Legal Advocate
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock By Investing.com - Investing.com India
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock - Investing.com UK
Evnin-linked funds sell 171K Werewolf Therapeutics (HOWL) shares - Stock Titan
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
Werewolf Therapeutics (HOWL) Stock: Down -3.84%, Support Test at $0.47 2026-05-18ATR Levels - newser.com
Werewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14 - MSN
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Should You Sell Werewolf Therapeutics (HOWL) After -5.07% Drop? 2026-05-17Head and Shoulders - Newser
Werewolf Therapeutics (HOWL) Reports Strong Q4 2025 — Revenue $N/A, EPS BeatsCommunity Watchlist - Newser
RA Capital funds sell HOWL shares, report 12.6% Werewolf Therapeutics stake - Stock Titan
News | Struggling Boston biotech firm cuts ties with headquarters space - CoStar
Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing - Moomoo
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation - Yahoo Finance
HOWL Director Luke Evnin Sells 44,679 Shares on May 13, 2026 - Meyka
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock By Investing.com - Investing.com Australia
Evnin-linked funds sell 44,679 Werewolf (NASDAQ: HOWL) shares under plan - Stock Titan
Werewolf Therapeutics vacates Watertown headquarters as cash dwindles - The Business Journals
TradingKey - TradingKey
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock - Investing.com India
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):